产品: | Flt3 / CD135 抗体 |
货号: | AF4727 |
描述: | Rabbit polyclonal antibody to Flt3 / CD135 |
应用: | WB |
反应: | Human, Mouse, Rat, Monkey |
预测: | Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog |
分子量: | 113kDa; 113kD(Calculated). |
蛋白号: | P36888 |
RRID: | AB_2844728 |
产品描述
*The optimal dilutions should be determined by the end user.
*Tips:
WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.
引用格式: Affinity Biosciences Cat# AF4727, RRID:AB_2844728.
展开/折叠
CD 135; CD135; CD135 antigen; Fetal liver kinase 2; FL cytokine receptor; Flk 2; Flk2; Flt 3; FLT-3; Flt3; FLT3_HUMAN; FMS like tyrosine kinase 3; Fms related tyrosine kinase 3; Fms-like tyrosine kinase 3; Growth factor receptor tyrosine kinase type III; Ly-72; OTTHUMP0000004234; Receptor type tyrosine protein kinase FLT3; Stem cell tyrosine kinase 1; Stk 1; STK-1; Stk1; Tyrosine protein kinase receptor FLT3; Tyrosine-protein kinase receptor FLT3;
抗原和靶标
Detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in granulocyte/macrophage progenitor cells (at protein level). Detected in bone marrow, liver, thymus, spleen and lymph node, and at low levels in kidney and pancreas. Highly expressed in T-cell leukemia.
- P36888 FLT3_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MPALARDGGQLPLLVVFSAMIFGTITNQDLPVIKCVLINHKNNDSSVGKSSSYPMVSESPEDLGCALRPQSSGTVYEAAAVEVDVSASITLQVLVDAPGNISCLWVFKHSSLNCQPHFDLQNRGVVSMVILKMTETQAGEYLLFIQSEATNYTILFTVSIRNTLLYTLRRPYFRKMENQDALVCISESVPEPIVEWVLCDSQGESCKEESPAVVKKEEKVLHELFGTDIRCCARNELGRECTRLFTIDLNQTPQTTLPQLFLKVGEPLWIRCKAVHVNHGFGLTWELENKALEEGNYFEMSTYSTNRTMIRILFAFVSSVARNDTGYYTCSSSKHPSQSALVTIVEKGFINATNSSEDYEIDQYEEFCFSVRFKAYPQIRCTWTFSRKSFPCEQKGLDNGYSISKFCNHKHQPGEYIFHAENDDAQFTKMFTLNIRRKPQVLAEASASQASCFSDGYPLPSWTWKKCSDKSPNCTEEITEGVWNRKANRKVFGQWVSSSTLNMSEAIKGFLVKCCAYNSLGTSCETILLNSPGPFPFIQDNISFYATIGVCLLFIVVLTLLICHKYKKQFRYESQLQMVQVTGSSDNEYFYVDFREYEYDLKWEFPRENLEFGKVLGSGAFGKVMNATAYGISKTGVSIQVAVKMLKEKADSSEREALMSELKMMTQLGSHENIVNLLGACTLSGPIYLIFEYCCYGDLLNYLRSKREKFHRTWTEIFKEHNFSFYPTFQSHPNSSMPGSREVQIHPDSDQISGLHGNSFHSEDEIEYENQKRLEEEEDLNVLTFEDLLCFAYQVAKGMEFLEFKSCVHRDLAARNVLVTHGKVVKICDFGLARDIMSDSNYVVRGNARLPVKWMAPESLFEGIYTIKSDVWSYGILLWEIFSLGVNPYPGIPVDANFYKLIQNGFKMDQPFYATEEIYIIMQSCWAFDSRKRPSFPNLTSFLGCQLADAEEAMYQNVDGRVSECPHTYQNRRPFSREMDLGLLSPQAQVEDS
种属预测
score>80的预测可信度较高,可尝试用于WB检测。*预测模型主要基于免疫原序列比对,结果仅作参考,不作为质保凭据。
High(score>80) Medium(80>score>50) Low(score<50) No confidence
翻译修饰 - P36888 作为底物
Site | PTM Type | Enzyme | Source |
---|---|---|---|
N43 | N-Glycosylation | Uniprot | |
N100 | N-Glycosylation | Uniprot | |
N151 | N-Glycosylation | Uniprot | |
Y166 | Phosphorylation | Uniprot | |
N306 | N-Glycosylation | Uniprot | |
N323 | N-Glycosylation | Uniprot | |
T343 | Phosphorylation | Uniprot | |
N351 | N-Glycosylation | Uniprot | |
N354 | N-Glycosylation | Uniprot | |
Y416 | Phosphorylation | Uniprot | |
Y572 | Phosphorylation | P36888 (FLT3) | Uniprot |
S574 | Phosphorylation | Uniprot | |
Y589 | Phosphorylation | P36888 (FLT3) | Uniprot |
Y591 | Phosphorylation | P36888 (FLT3) , P11309 (PIM1) | Uniprot |
Y597 | Phosphorylation | P36888 (FLT3) | Uniprot |
Y599 | Phosphorylation | P36888 (FLT3) | Uniprot |
K602 | Ubiquitination | Uniprot | |
K614 | Ubiquitination | Uniprot | |
K623 | Ubiquitination | Uniprot | |
Y630 | Phosphorylation | Uniprot | |
K634 | Ubiquitination | Uniprot | |
K644 | Ubiquitination | Uniprot | |
K719 | Ubiquitination | Uniprot | |
Y726 | Phosphorylation | P36888 (FLT3) | Uniprot |
T728 | Phosphorylation | Uniprot | |
S759 | Phosphorylation | Uniprot | |
Y768 | Phosphorylation | P36888 (FLT3) | Uniprot |
K772 | Ubiquitination | Uniprot | |
Y793 | Phosphorylation | P36888 (FLT3) | Uniprot |
S840 | Phosphorylation | Uniprot | |
Y842 | Phosphorylation | P36888 (FLT3) | Uniprot |
Y919 | Phosphorylation | Uniprot | |
K932 | Ubiquitination | Uniprot | |
S935 | Phosphorylation | Uniprot | |
Y955 | Phosphorylation | P36888 (FLT3) | Uniprot |
T968 | Phosphorylation | Uniprot | |
Y969 | Phosphorylation | P36888 (FLT3) | Uniprot |
S993 | Phosphorylation | Uniprot |
翻译修饰 - P36888 作为激酶
Substrate | Site | Source |
---|---|---|
P29353-7 (SHC1) | Y239 | Uniprot |
P29353-7 (SHC1) | Y240 | Uniprot |
P29353-7 (SHC1) | Y318 | Uniprot |
P29353 (SHC1) | Y349 | Uniprot |
P29353 (SHC1) | Y350 | Uniprot |
P29353 (SHC1) | Y427 | Uniprot |
P35222 (CTNNB1) | Y654 | Uniprot |
P36888 (FLT3) | Y572 | Uniprot |
P36888 (FLT3) | Y589 | Uniprot |
P36888 (FLT3) | Y591 | Uniprot |
P36888 (FLT3) | Y597 | Uniprot |
P36888-1 (FLT3) | Y599 | Uniprot |
P36888 (FLT3) | Y726 | Uniprot |
P36888 (FLT3) | Y768 | Uniprot |
P36888 (FLT3) | Y793 | Uniprot |
P36888 (FLT3) | Y842 | Uniprot |
P36888 (FLT3) | Y955 | Uniprot |
P36888 (FLT3) | Y969 | Uniprot |
Q15118 (PDK1) | Y243 | Uniprot |
研究背景
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.
N-glycosylated, contains complex N-glycans with sialic acid.
Autophosphorylated on several tyrosine residues in response to FLT3LG binding. FLT3LG binding also increases phosphorylation of mutant kinases that are constitutively activated. Dephosphorylated by PTPRJ/DEP-1, PTPN1, PTPN6/SHP-1, and to a lesser degree by PTPN12. Dephosphorylation is important for export from the endoplasmic reticulum and location at the cell membrane.
Rapidly ubiquitinated by UBE2L6 and the E3 ubiquitin-protein ligase SIAH1 after autophosphorylation, leading to its proteasomal degradation.
Membrane>Single-pass type I membrane protein. Endoplasmic reticulum lumen.
Note: Constitutively activated mutant forms with internal tandem duplications are less efficiently transported to the cell surface and a significant proportion is retained in an immature form in the endoplasmic reticulum lumen. The activated kinase is rapidly targeted for degradation.
Detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in granulocyte/macrophage progenitor cells (at protein level). Detected in bone marrow, liver, thymus, spleen and lymph node, and at low levels in kidney and pancreas. Highly expressed in T-cell leukemia.
Monomer in the absence of bound FLT3LG. Homodimer in the presence of bound FLT3LG. Interacts with FIZ1 following ligand activation (By similarity). Interacts with FES, FER, LYN, FGR, HCK, SRC and GRB2. Interacts with PTPRJ/DEP-1 and PTPN11/SHP2. Interacts with RNF115 and RNF126 (By similarity).
(Microbial infection) Interacts with human cytomegalovirus protein UL7.
The juxtamembrane autoregulatory region is important for normal regulation of the kinase activity and for maintaining the kinase in an inactive state in the absence of bound ligand. Upon tyrosine phosphorylation, it mediates interaction with the SH2 domains of numerous signaling partners. In-frame internal tandem duplications (ITDs) result in constitutive activation of the kinase. The activity of the mutant kinase can be stimulated further by FLT3LG binding.
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
研究领域
· Environmental Information Processing > Signal transduction > MAPK signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > Ras signaling pathway. (View pathway)
· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction. (View pathway)
· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway. (View pathway)
· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)
· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.
· Human Diseases > Cancers: Specific types > Acute myeloid leukemia. (View pathway)
· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer. (View pathway)
· Organismal Systems > Immune system > Hematopoietic cell lineage. (View pathway)
限制条款
产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。
产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。
Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。产品仅供科学研究使用。不用于诊断和治疗。
产品未经授权不得转售。
Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.